Esperion to Report First Quarter 2025 Financial Results on May 6
Esperion (NASDAQ: ESPR) has announced it will release its first quarter 2025 financial results on Tuesday, May 6, 2025, before market opening.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Esperion (NASDAQ: ESPR) has announced it will release its first quarter 2025 financial results on Tuesday, May 6, 2025, before market opening. The company will host a webcast at 8:00 a.m. ET to discuss the results and provide business updates.
Esperion is a commercial stage biopharmaceutical company that develops and commercializes FDA-approved oral, once-daily, non-statin medicines for patients with cardiovascular disease and elevated LDL-C. Their medications are supported by the CLEAR Cardiovascular Outcomes Trial, which included nearly 14,000 patients.
The company is also advancing its next generation program focusing on ATP citrate lyase inhibitors (ACLYi), utilizing new insights into structure and function for rational drug design of highly potent and specific inhibitors with allosteric mechanisms.
Positive
- FDA-approved oral, once-daily, non-statin medicines in commercial stage
- Large-scale clinical validation with 14,000-patient CLEAR trial
- Advancing next-generation ACLYi drug development program
Negative
- None.
Details
News Market Reaction – ESPR
The recorded move for ESPR in the trading session of this news was +2.10%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ANN ARBOR, Mich., April 23, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2025 financial results before the market opens on Tuesday, May 6, 2025.
Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates.
A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.
Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.
Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and follow Esperion on LinkedIn and X.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.